Is BMY.SW stock a buy after the drop?

BMY.SW stock may offer a short‑term bounce, but it carries medium‑term downside per the Meyka AI yearly forecast of CHF 39.34. Use small position sizes and wait for confirmation near the 50‑day average before scaling.

What are the main valuation metrics for BMY.SW stock?

BMY.SW stock trades at PE **15.99** with EPS **2.66** and a free cash flow yield of **23.36%**. The company pays a dividend yield near **3.50%**, while debt remains elevated at a debt to equity of **2.75**.

How does sector performance affect BMY.SW stock?

Healthcare strength can support BMY.SW stock recoveries. The sector average PE is **35.33**, making BMY appear cheaper on PE. Sector approvals or favourable data often lift shares across the group.

What short‑term targets should traders watch for BMY.SW stock?

For an oversold bounce, watch the 50‑day average at **CHF 43.75** and near‑term resistance at **CHF 44.50**. A failure below **CHF 42.54** increases downside risk toward the forecasted level of **CHF 39.34**.

CH Stocks

CHF42.54 close: BMY.SW Bristol-Myers Squibb (SIX) 27 Feb 2026 oversold bounce

ByDanny Kontos February 27, 2026February 27, 2026

BMY.SW stock closed at CHF 42.54 on the SIX market on 27 Feb 2026, down 4.40% from the previous close. The drop left volume light at 500.00 shares but pushed the share price below the 50‑day average of CHF 43.75, setting a short‑term oversold bounce condition. Traders watching an oversold bounce will compare the quick pullback to earnings, debt metrics and cash flow to judge a recovery. This note uses on‑chain metrics and Meyka AI powered market analysis to map risk and a near‑term price path for investors on the Swiss exchange.